Clinical Trial Update: Pyramax in Asymptomatic Carriers of P. Falciparum Monoinfections [Phase 2]

View source ↗

Summary

Phase 2 trial update for Pyramax in asymptomatic carriers of Plasmodium falciparum monoinfections; status not disclosed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malaria

Drugs mentioned

• Pyramax (pyronaridine-artesunate)

Snippet

Sponsor: Shin Poong Pharmaceutical Co. Ltd. | Conditions: Malaria,Falciparum | Phase 2 | Status: UNKNOWN